Literature DB >> 28050620

[Commentary to: Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis].

C S Bruells1, R Kopp2.   

Abstract

Entities:  

Year:  2017        PMID： 28050620     DOI： 10.1007/s00101-016-0255-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN： 0003-2417            Impact factor:   1.041


× No keyword cloud information.
  5 in total

1.  Increased fluid administration in the first three hours of sepsis resuscitation is associated with reduced mortality: a retrospective cohort study.

Authors:  Sarah J Lee; Kannan Ramar; John G Park; Ognjen Gajic; Guangxi Li; Rahul Kashyap
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

2.  A randomized trial of protocol-based care for early septic shock.

Authors:  Donald M Yealy; John A Kellum; David T Huang; Amber E Barnato; Lisa A Weissfeld; Francis Pike; Thomas Terndrup; Henry E Wang; Peter C Hou; Frank LoVecchio; Michael R Filbin; Nathan I Shapiro; Derek C Angus
Journal:  N Engl J Med       Date:  2014-03-18       Impact factor: 91.245

3.  The calcium sensitizer levosimendan improves human diaphragm function.

Authors:  Jonne Doorduin; Christer A Sinderby; Jennifer Beck; Dick F Stegeman; Hieronymus W H van Hees; Johannes G van der Hoeven; Leo M A Heunks
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

4.  Goal-directed resuscitation for patients with early septic shock.

Authors:  Sandra L Peake; Anthony Delaney; Michael Bailey; Rinaldo Bellomo; Peter A Cameron; D James Cooper; Alisa M Higgins; Anna Holdgate; Belinda D Howe; Steven A R Webb; Patricia Williams
Journal:  N Engl J Med       Date:  2014-10-01       Impact factor: 91.245

5.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

Authors:  F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.